Circular Genomics

United States
Chico, California, United States

Company profile

Circular Genomics company profile

Circular Genomics develops circular RNA (circRNA)-based diagnostic and biomarker tools for neurological and psychiatric disorders. The company uses brain-derived circRNAs, a class of stable non-coding RNA molecules enriched in the brain, to build blood-based assays that reflect disease biology in real time. Its first product, MindLight™, predicts whether a patient with major depressive disorder will respond to SSRI antidepressants. Circular Genomics is also creating additional assays designed for early detection and risk prediction of neurodegenerative diseases such as Alzheimer’s disease. The company applies its circRNA platform to help clinicians make more informed treatment decisions using molecular indicators of brain health.

Business identity

Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2021-01-01, Year

Headquarters

Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
5
Total equity funding
$27.8M
Last funding
Series A / $15M / 2025-12-01
Last equity funding
Series A / $15M
Investors
8
Lead investors
5
Founders
3
Articles
42

Founders and investors

Founders

Alexander HafezKosmas KaradimitriouNikolaos Mellios

Lead investors

Alzheimer's Drug Discovery FoundationCottonwood Technology FundMountain Group CapitalNew Mexico Economic Development DepartmentTramway Venture Partners

Investors

Alzheimer's Drug Discovery FoundationCottonwood Technology FundMountain Group CapitalNew Mexico Economic Development DepartmentTramway Venture Partners